Hui-Qi Liu

Hui-Qi Liu

Auto-generated profile, based on publicly available information

Hui-Qi Liu

Clinical Medical College of Qinghai University, Qinghai 810001, Xining Province, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
HLHui-Qi Liu
Hui-Qi Liu
LSLixin Sun
Lixin Sun
LYLong Yu
Long Yu
JLJun Liu
Jun Liu
LSLi-Chao Sun
Li-Chao Sun
YRYu-Liang Ran
Yu-Liang Ran
Background: Identification of promising targeted antigens that exhibited cancer-specific expression is a crucial step in the development of novel antibody-targeted therapies. We here aimed to investigate the anti-tumor activity of a novel monoclonal antibody (mAb) 11C9 and identify the antibody tractable target in the hepatocellular cancer stem cells (HCSCs). Methods: The identification of the targeted antigen was conducted using SDS-PAGE, western blot, mass spectrometry, and co-immunoprecipitation. Silence of HSP90 was induced by siRNA interference. Positive cells were sorted by fluorescence-activated cell sorting. Double-immunofluorescent (IF) staining and two-color flow cytometry detected the co-expression. Self-renewal, invasion, and drug resistance were assessed by sphere formation, matrigel-coated Transwell assay, and CCK-8 assay, respectively. Tumorigenicity was evaluated in mouse xenograft models. RNA-seq and bioinformatics analysis were performed to explore the mechanism of mAb 11C9 and potential targets. Results: MAb 11C9 inhibited invasion and self-renewal abilities of HCC cell lines and reversed the cisplatin resistance. HSP90 (~ 95 kDa) was identified as a targeted antigen of mAb 11C9. Tissue microarrays and online databases revealed that HSP90 was overexpressed in HCC and associated with a poor prognosis. FACS and double-IF staining showed the co-expression of HSP90 and CSCs markers (CD90 and ESA). In vitro and in vivo demonstrated the tumorigenic potentials of HSP90. The inhibition of HSP90 by siRNA interference or 17-AAG inhibitor both decreased the number of invasion, sphere cells, and CD90+ or ESA+ cells, as well as reversed the resistance. Bioinformatics analysis and western blot verified that HSP90 activated Wnt/β-catenin signaling. Conclusions: The study preliminarily revealed the anti-tumor activity of mAb 11C9. More importantly, we identified HSP90 as a targeted antigen of mAb 11C9, which functions as an oncogene in phenotype shaping, stemness maintenance, and therapeutic resistance by activating Wnt/β-catenin signaling.

30 September 2024 in Oncology Treatment Discovery
Verified
Journal Article
Open access
PDF file
BGBaoming Guo
Baoming Guo
ZJZheng Jiao
Zheng Jiao
JLJianzhou Li
Jianzhou Li
JPJing Pan
Jing Pan
HLHuiqi Liu
Huiqi Liu
Objective: To investigate the expression of Doublecortin-like kinase-1 (DCLK1) in the serum of gastric cancer patients and its relationship with carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 72-4 (CA72-4). Methods: Fifty patients diagnosed with gastric cancer at the hospital from January to December 2021 were selected as the gastric cancer group, and 50 patients diagnosed with chronic atrophic gastritis during the same period were selected as the control group. The serum concentrations of DCLK1, CEA, CA19-9, and CA72-4 were measured in both groups. Cut-off values and AUC (Area Under the Curve) were determined based on the ROC curve, and the expression of DCLK1 and its relationship with CEA, CA19-9, and CA72-4 were analyzed. Results: The average concentrations of DCLK1, CEA, CA19-9, and CA72-4 in the serum of gastric cancer patients were significantly higher than those in the control group (P < 0.05). CA72-4 had the highest sensitivity (62%), CEA had the highest specificity (98%), and DCLK1 had the largest AUC (0.709). The combined diagnosis of gastric cancer using DCLK1, CEA, and CA19-9 resulted in the largest AUC (0.826), with a sensitivity of 82% and a specificity of 76%. Conclusion: The expression of DCLK1, CEA, CA19-9, and CA72-4 in the serum of gastric cancer patients is significantly higher than that in the control group. The combined detection of DCLK1, CEA, and CA19-9 offers better sensitivity and specificity for the diagnosis of gastric cancer.